Metastatic melanoma in the older patient: Special considerations

Clinics in Dermatology

Volumn 31, Issue 3, 2013, Pages 311-316

  Hegde, Upendra P ^a   Grant Kels, Jane M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; INTERLEUKIN 2; MELANOMA VACCINE; VEMURAFENIB;

AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; CUTANEOUS MELANOMA; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EARLY DIAGNOSIS; GENE MUTATION; GERIATRIC PATIENT; HUMAN; IMMUNE SYSTEM; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84876724853     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.011     Document Type: Article

References (31)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Bleyer A., Barr R., Hayes-Lattin B., et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev 2008, 8:288-298.
3. Jemal A., Siegel R., Xu J., Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. McAllister S.S., Weinberg R.A. Tumor-host interactions: a far-reaching relationship. J Clin Oncol 2010, 28:4022-4028.
5. Simard E.P., Ward E.M., Siegal R., Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012, 62:118-128.
6. Geller A.C., Sober A.J., Zhang Z., et al. Strategies for improving melanoma education and screening for men age >or =50 years: findings from the American Academy of Dermatological National Skin Cancer Screening Program. Cancer 2002, 95:1554-1561.
7. Cohen H.J., Cox E., Manton K., Woodbury M. Malignant melanoma in the elderly. J Clin Oncol 1987, 5:100-106.
8. Averbook B.J., Russo L.J., Mansour E.G. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 1998, 124:746-756.
9. Chang C.K., Jacobs I.A., Vizgirda V.M., Salti G. Melanoma in the elderly patient. Arch Surg 2003, 138:1135-1138.
10. Balch C.M., Soong S.-J., Gershenwald J.E., et al. prognostic factor analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
11. Chao C., Martin R.C., Ross M.I., et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004, 11:259-264.
12. Azim H.A., Michiels S., Bedard P.L., et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012, 18:1341-1351.
13. Garavello W., Spreafico R., Gaini R.M. Oral tongue cancer in young patients: a matched analysis. Oral Oncol 2007, 43:894-897.
14. Smith B.R., Stabile B.E. Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg 2009, 144:506-510.
15. Brand C.U., Ellwanger U., Stroebel W., et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. Cancer 1997, 79:2345-2353.
16. Eton O., Legha S.S., Moon T.E., et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998, 16:1103-1111.
17. Francken A.B., Accortt N.A., Shaw H.M., et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2007, 15:1476-1484.
18. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
19. Legha S.S., Ring S., Bedikian A., et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine, dacarbazine (CVD) and biotherapy using interleukin-2 and interferon alpha. Ann Oncol 1996, 7:827-835.
20. Atzpodien J., Wandert T., Reitz M. Age does not impair the efficacy of immunotherapy in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2005, 55:193-199.
21. Quan W., Ramirez M., Taylor C., et al. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over. Cancer Biother Radiopharm 2005, 20:11-15.
22. Derhovanessian E., Solana R., Larbi A., Pawelec G. Immunity, ageing and cancer. Immun Ageing 2008, 5:11.
23. Lauerova L., Dusek L., Simickova M., et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002, 49:159-166.
24. Hegde U.P., Chakraborty N., Mukherji B., Grant Kels J. Metastatic melanoma in the older patient: immunologic insights and treatment outcomes. Expert Rev Pharmacoecon Outcomes Res 2011, 11:185-193.
25. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexure in human tumors: impact on clinical outcome. Nat Rev Cancer 2012, 12:298-306.
26. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
27. Van der Meijden, van Bruchem-Visser R.L., Thio H.B., van der Cammen T.J. Melanomas more serious in the elderly. Ned Tijdschr Geneeskd 2010, 154:A1535-A.
28. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
29. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
30. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 8:426-433.
31. Galon J., Pages F., Marincola F.M., et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1.